# US 2025/0367242 A1 · Designed bacterial compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367242 A1
- Document ID: US20250367242A1
- Status: Published application
- Kind: A1
- Application number: 19/046,341
- Filed: 2025-02-05
- Published: 2025-12-04
- Earliest claimed: 2018-05-24
- Assignees: Seres Therapeutics, Inc.
- Applicants: Seres Therapeutics, Inc.
- Inventors: Asuncion MARTINEZ; Edward J. O'BRIEN; Sheri Lynn SIMMONS; David COOK; Matthew R. HENN; Christopher B. FORD; Divya BALASUBRAMANIAN; Ambar PIÑA; Liyang DIAO; Meghan CHAFEE; Marin VULIC; Madhumitha NANDAKUMAR; Sumon DATTA; Lata JAYARAMAN
- Web page: https://patentgrep.com/patent/US20250367242A1

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/745: Bifidobacteria
- A61K 38/18: Growth factors; Growth regulators
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 1/20: Bacteria; Culture media therefor
- A61K 2035/115: {Probiotics}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are bacterial compositions that are useful for treating and preventing complications and side effects associated with a disease or disorder, such as those associated with dysbiosis of a gastrointestinal tract. The bacterial compositions disclosed herein are designed to exhibit one or more functional features that are useful for the treatment of such diseases and disorders.

## Claims

### Claim 1

A composition comprising a first purified bacterial population and a second purified bacterial population,
wherein the first purified bacterial population comprises one or more bacteria having a 16S rDNA sequence that is at least 97% identical to a 16S rDNA sequence set forth in SEQ ID NO: 215, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 188, SEQ ID NO: 212, SEQ ID NO: 160, SEQ ID NO: 186, SEQ ID NO: 203, SEQ ID NO: 104, SEQ ID NO: 208, SEQ ID NO: 189, SEQ ID NO: 187, SEQ ID NO: 207, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 211, SEQ ID NO: 209, SEQ ID NO: 110, SEQ ID NO: 150, SEQ ID NO: 175, SEQ ID NO: 158, SEQ ID NO: 210, or SEQ ID NO: 106, and
wherein the second purified bacterial population comprises one or more bacteria having one or more features selected from the group consisting of: (i) capable of engrafting when administered to a subject, (ii) capable of having anti-inflammatory activity, (iii) not capable of inducing pro-inflammatory activity, (iv) capable of producing a secondary bile acid, (v) capable of producing a tryptophan metabolite, (vi) capable of restoring epithelial integrity as determined by a primary epithelial cell monolayer barrier integrity assay, (vii) capable of being associated with remission of an inflammatory bowel disease, (viii) capable of producing a short-chain fatty acid, (ix) capable of inhibiting a HDAC activity, (x) capable of producing a middle-chain fatty acid, (xi) capable of expressing catalase activity, (xii) capable of having alpha-fucosidase activity, (xiii) capable of inducing Wnt activation, (xiv) capable of producing a B vitamin, (xv) capable of modulating host metabolism of endocannabinoid, (xvi) capable of producing a polyamine and/or modulating a host metabolism of a polyamine, (xvii) capable of reducing fecal levels of a sphingolipid, (xviii) capable of modulating host production of kynurenine, (xix) capable of reducing fecal calprotectin level, (xx) not capable of activating a toll-like receptor pathway (e.g., TLR2 or TLR5), (xxi) capable of activating a toll-like receptor pathway (e.g., TLR2 or TLR5), and (xxii) any combination thereof.

### Claim 2 (depends on 1)

The composition of claim 1,
which further comprises one or more bacteria having a 16S rDNA sequence that is at least 97% identical to a 16S rDNA sequence set forth in SEQ ID NO: 118, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 137, SEQ ID NO: 117, SEQ ID NO: 137, SEQ ID NO: 111, or SEQ ID NO: 103.

### Claim at position 3

3-15. (canceled)

### Claim 16

A composition comprising a purified bacterial population, wherein the purified bacterial population comprises two or more features selected from the group consisting of: (i) capable of engrafting when administered to a subject, (ii) capable of having anti-inflammatory activity, (iii) not capable of inducing pro-inflammatory activity, (iv) capable of producing a secondary bile acid, (v) capable of producing a tryptophan metabolite, (vi) capable of restoring epithelial integrity as determined by a primary epithelial cell monolayer barrier integrity assay, (vii) capable of being associated with remission of an inflammatory bowel disease, (viii) capable of producing a short-chain fatty acid, (ix) capable of inhibiting a HDAC activity, (x) capable of producing a middle-chain fatty acid, (xi) capable of expressing catalase activity, (xii) capable of having alpha-fucosidase activity, (xiii) capable of inducing Wnt activation, (xiv) capable of producing a B vitamin, (xv) capable of modulating host metabolism of endocannabinoid, (xvi) capable of producing a polyamine and/or modulating a host metabolism of a polyamine, (xvii) capable of reducing fecal levels of a sphingolipid, (xviii) capable of modulating host production of kynurenine, (xix) capable of reducing fecal calprotectin level, (xx) not capable of activating a toll-like receptor pathway (e.g., TLR2 or TLR5), (xxi) capable of activating a toll-like receptor pathway (e.g., TLR2 or TLR5), and (xxii) any combination thereof.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The composition of claim 16, wherein the purified bacterial population comprises one or more bacteria having a 16S rDNA sequence that is at least 97% identical to a 16S rDNA sequence set forth in:
(i) SEQ ID NO: 215, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 188, SEQ ID NO: 212, SEQ ID NO: 160, SEQ ID NO: 186, SEQ ID NO: 203, SEQ ID NO: 104, SEQ ID NO: 208, SEQ ID NO: 189, SEQ ID NO: 187, SEQ ID NO: 207, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 211, SEQ ID NO: 209, SEQ ID NO: 110, SEQ ID NO: 159, SEQ ID NO: 175, SEQ ID NO: 158, SEQ ID NO: 210, or SEQ ID NO: 106; or
(ii) SEQ ID NO: 185, SEQ ID NO: 183, SEQ ID NO: 161, SEQ ID NO: 206, SEQ ID NO: 102, SEQ ID NO: 214, SEQ ID NO: 184, SEQ ID NO: 204, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 109, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 192, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 107, SEQ ID NO: 137, SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 133, SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 103, SEQ ID NO: 108, SEQ ID NO: 124, SEQ ID NO: 165, SEQ ID NO: 136, SEQ ID NO: 125, SEQ ID NO: 111, SEQ ID NO: 164, SEQ ID NO: 205, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 162, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 105, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 163, SEQ ID NO: 182, SEQ ID NO: 135, SEQ ID NO: 134, SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, or SEQ ID NO: 213.

### Claim at position 7

19-20. (canceled)

### Claim 21 (depends on 20)

The composition of claim 20, wherein the purified bacterial population further comprises one or more bacteria, which has one or more features selected from the group consisting of: (i) capable of engrafting when administered to a subject, (ii) capable of having anti-inflammatory activity, (iii) not capable of inducing pro-inflammatory activity, (iv) capable of producing a secondary bile acid, (v) capable of producing a tryptophan metabolite, (vi) capable of restoring epithelial integrity as determined by a primary epithelial cell monolayer barrier integrity assay, (vii) capable of being associated with remission of an inflammatory bowel disease, (viii) capable of producing a short-chain fatty acid, (ix) capable of inhibiting a HDAC activity, (x) capable of producing a middle-chain fatty acid, (xi) capable of expressing catalase activity, (xii) capable of having alpha-fucosidase activity, (xiii) capable of inducing Wnt activation, (xiv) capable of producing a B vitamin, (xv) capable of modulating host metabolism of endocannabinoid, (xvi) capable of producing a polyamine and/or modulating host metabolism of polyamines, (xvii) capable of reducing fecal levels of a sphingolipid, (xviii) capable of modulating host production of kynurenine, (xix) capable of reducing fecal calprotectin level, (xx) not capable of activating a toll-like receptor pathway (e.g., TLR2 or TLR5), (xxi) capable of activating a toll-like receptor pathway (e.g., TLR2 or TLR5), and (xxii) any combination thereof.

### Claim at position 9

22-37. (canceled)

### Claim 38 (depends on 1)

The composition of claim 1, wherein the first purified bacterial population and/or the second purified bacterial population does not comprise a bacterium having 7β-hydroxysteroid dehydrogenase (7-HSDH) activity.

### Claim at position 11

39-47. (canceled)

### Claim 48 (depends on 20)

The composition of claim 20, wherein (i) the long-term engrafter has a 16S rDNA sequence that is at least 97% identical to a 16S rDNA sequence of a long-term engrafter provided in Table 5; (ii) the transient engrafter has a 16S rDNA sequence that is at least 97% identical to a 16S rDNA sequence of a transient engrafter provided in Table 5; or (iii) both (i) and (ii).

### Claim at position 13

49-51. (canceled)

### Claim 52

A composition comprising a purified bacterial population, which comprises one or more bacteria having a 16S rDNA sequence that is at least 97% identical to a 16S rDNA sequence set forth in SEQ ID NO: 215, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 188, SEQ ID NO: 212, SEQ ID NO: 160, SEQ ID NO: 186, SEQ ID NO: 203, SEQ ID NO: 104, SEQ ID NO: 208, SEQ ID NO: 189, SEQ ID NO: 187, SEQ ID NO: 207, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 211, SEQ ID NO: 209, SEQ ID NO: 110, SEQ ID NO: 159, SEQ ID NO: 175, SEQ ID NO: 158, SEQ ID NO: 210, or SEQ ID NO: 106.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the purified bacterial population further comprises one or more bacteria having a 16S rDNA sequence that is at least 97% identical to a 16S rDNA sequence set forth in SEQ ID NO: 185, SEQ ID NO: 183, SEQ ID NO: 161, SEQ ID NO: 206, SEQ ID NO: 102, SEQ ID NO: 214, SEQ ID NO: 184, SEQ ID NO: 204, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 109, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 192, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO: 107, SEQ ID NO: 137, SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 133, SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 103, SEQ ID NO: 108, SEQ ID NO: 124, SEQ ID NO: 165, SEQ ID NO: 136, SEQ ID NO: 125, SEQ ID NO: 111, SEQ ID NO: 164, SEQ ID NO: 205, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 162, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 105, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 163, SEQ ID NO: 182, SEQ ID NO: 135, SEQ ID NO: 134, SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO: 181, or SEQ ID NO: 213.

### Claim at position 16

54-55. (canceled)

### Claim 56 (depends on 1)

The composition of claim 1, (i) further comprising one or more enteric polymers, (ii) which is lyophilized, (iii) formulated for oral delivery, or (iv) any combination of (i) to (iii).

### Claim 57 (depends on 1)

A pharmaceutical formulation comprising the composition of claim 1, and a pharmaceutically acceptable excipient.

### Claim at position 19

58-60. (canceled)

### Claim 61 (depends on 1)

A method of treating an inflammatory disease in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1.

### Claim 62

(canceled)

### Claim 63 (depends on 61)

The method of claim 61- or 62, wherein the inflammatory disease comprises an inflammatory bowel disease.

### Claim at position 23

64-66. (canceled)

### Claim 67 (depends on 1)

A method of modulating the level of a biological molecule in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1.

### Claim 68 (depends on 67)

The method of claim 67, wherein the biological molecule comprises a fecal calprotectin, a secondary bile acid, a tryptophan metabolite, a short-chain fatty acid, a medium-chain fatty acid, a sphingolipid, a kynurenine, or any combination thereof.

### Claim at position 26

69-77. (canceled)

### Claim 78 (depends on 1)

A method of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1.

### Claim at position 28

79-80. (canceled)

### Claim 81 (depends on 1)

A method for inhibiting a growth of a tumor or reducing the size of a tumor in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1.

### Claim at position 30

82-83. (canceled)

### Claim 84 (depends on 1)

A method of enhancing an immune response in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1.

### Claim at position 32

85-90. (canceled)

### Claim 91 (depends on 78)

The method claim 78, wherein the cancer comprises a bladder cancer, breast cancer, uterine/cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, kidney cancer, head and neck cancer, lung cancer, stomach cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, neoplasm of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, virus-related cancer, or any combination thereof.

### Claim at position 34

92-94. (canceled)
